Cargando…

Multilevel latent class casemix modelling: a novel approach to accommodate patient casemix

BACKGROUND: Using routinely collected patient data we explore the utility of multilevel latent class (MLLC) models to adjust for patient casemix and rank Trust performance. We contrast this with ranks derived from Trust standardised mortality ratios (SMRs). METHODS: Patients with colorectal cancer d...

Descripción completa

Detalles Bibliográficos
Autores principales: Gilthorpe, Mark S, Harrison, Wendy J, Downing, Amy, Forman, David, West, Robert M
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062580/
https://www.ncbi.nlm.nih.gov/pubmed/21362172
http://dx.doi.org/10.1186/1472-6963-11-53
_version_ 1782200722634309632
author Gilthorpe, Mark S
Harrison, Wendy J
Downing, Amy
Forman, David
West, Robert M
author_facet Gilthorpe, Mark S
Harrison, Wendy J
Downing, Amy
Forman, David
West, Robert M
author_sort Gilthorpe, Mark S
collection PubMed
description BACKGROUND: Using routinely collected patient data we explore the utility of multilevel latent class (MLLC) models to adjust for patient casemix and rank Trust performance. We contrast this with ranks derived from Trust standardised mortality ratios (SMRs). METHODS: Patients with colorectal cancer diagnosed between 1998 and 2004 and resident in Northern and Yorkshire regions were identified from the cancer registry database (n = 24,640). Patient age, sex, stage-at-diagnosis (Dukes), and Trust of diagnosis/treatment were extracted. Socioeconomic background was derived using the Townsend Index. Outcome was survival at 3 years after diagnosis. MLLC-modelled and SMR-generated Trust ranks were compared. RESULTS: Patients were assigned to two classes of similar size: one with reasonable prognosis (63.0% died within 3 years), and one with better prognosis (39.3% died within 3 years). In patient class one, all patients diagnosed at stage B or C died within 3 years; in patient class two, all patients diagnosed at stage A, B or C survived. Trusts were assigned two classes with 51.3% and 53.2% of patients respectively dying within 3 years. Differences in the ranked Trust performance between the MLLC model and SMRs were all within estimated 95% CIs. CONCLUSIONS: A novel approach to casemix adjustment is illustrated, ranking Trust performance whilst facilitating the evaluation of factors associated with the patient journey (e.g. treatments) and factors associated with the processes of healthcare delivery (e.g. delays). Further research can demonstrate the value of modelling patient pathways and evaluating healthcare processes across provider institutions.
format Text
id pubmed-3062580
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30625802011-03-23 Multilevel latent class casemix modelling: a novel approach to accommodate patient casemix Gilthorpe, Mark S Harrison, Wendy J Downing, Amy Forman, David West, Robert M BMC Health Serv Res Research Article BACKGROUND: Using routinely collected patient data we explore the utility of multilevel latent class (MLLC) models to adjust for patient casemix and rank Trust performance. We contrast this with ranks derived from Trust standardised mortality ratios (SMRs). METHODS: Patients with colorectal cancer diagnosed between 1998 and 2004 and resident in Northern and Yorkshire regions were identified from the cancer registry database (n = 24,640). Patient age, sex, stage-at-diagnosis (Dukes), and Trust of diagnosis/treatment were extracted. Socioeconomic background was derived using the Townsend Index. Outcome was survival at 3 years after diagnosis. MLLC-modelled and SMR-generated Trust ranks were compared. RESULTS: Patients were assigned to two classes of similar size: one with reasonable prognosis (63.0% died within 3 years), and one with better prognosis (39.3% died within 3 years). In patient class one, all patients diagnosed at stage B or C died within 3 years; in patient class two, all patients diagnosed at stage A, B or C survived. Trusts were assigned two classes with 51.3% and 53.2% of patients respectively dying within 3 years. Differences in the ranked Trust performance between the MLLC model and SMRs were all within estimated 95% CIs. CONCLUSIONS: A novel approach to casemix adjustment is illustrated, ranking Trust performance whilst facilitating the evaluation of factors associated with the patient journey (e.g. treatments) and factors associated with the processes of healthcare delivery (e.g. delays). Further research can demonstrate the value of modelling patient pathways and evaluating healthcare processes across provider institutions. BioMed Central 2011-03-01 /pmc/articles/PMC3062580/ /pubmed/21362172 http://dx.doi.org/10.1186/1472-6963-11-53 Text en Copyright ©2011 Gilthorpe et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Gilthorpe, Mark S
Harrison, Wendy J
Downing, Amy
Forman, David
West, Robert M
Multilevel latent class casemix modelling: a novel approach to accommodate patient casemix
title Multilevel latent class casemix modelling: a novel approach to accommodate patient casemix
title_full Multilevel latent class casemix modelling: a novel approach to accommodate patient casemix
title_fullStr Multilevel latent class casemix modelling: a novel approach to accommodate patient casemix
title_full_unstemmed Multilevel latent class casemix modelling: a novel approach to accommodate patient casemix
title_short Multilevel latent class casemix modelling: a novel approach to accommodate patient casemix
title_sort multilevel latent class casemix modelling: a novel approach to accommodate patient casemix
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062580/
https://www.ncbi.nlm.nih.gov/pubmed/21362172
http://dx.doi.org/10.1186/1472-6963-11-53
work_keys_str_mv AT gilthorpemarks multilevellatentclasscasemixmodellinganovelapproachtoaccommodatepatientcasemix
AT harrisonwendyj multilevellatentclasscasemixmodellinganovelapproachtoaccommodatepatientcasemix
AT downingamy multilevellatentclasscasemixmodellinganovelapproachtoaccommodatepatientcasemix
AT formandavid multilevellatentclasscasemixmodellinganovelapproachtoaccommodatepatientcasemix
AT westrobertm multilevellatentclasscasemixmodellinganovelapproachtoaccommodatepatientcasemix